Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

STAT3 Mutations and Anemia with Pure Red Cell Aplasia Are the Distinctive Features of T Cell Receptor Gamma Delta Type Large Granular Lymphocyte Leukemia

Taku Yamane, Toru Kawakami, MD, Nodoka Sekiguchi, MD PhD, Jun Kobayashi, Toshimitsu Ueki, MD, Hikaru Kobayashi, MD PhD, Sayaka Nishina, Kaoko Sakai, MD, Hitoshi Sakai, MD, Kazuo Oshimi, MD, Yumiko Higuchi, PhD, Hideyuki Nakazawa, MD PhD, Fumihiro Ishida, MD PhD

Blood (2019) 134 (Supplement_1): 1500.

https://doi.org/10.1182/blood-2019-123614

Published: 2019

Journal Articles

Prognostic Value Of LMP1, CLA, NK-Cell Origin, and Pretreatment Bone Marrow EBER-ISH In Localized NK/T-Cell Lymphoma Prospectively Treated With Concurrent Chemoradiotherapy: An Ancillary Study Of Japan Clinical Oncology Group (JCOG) 0211

Motoko Yamaguchi, MD, PhD, Katsuyoshi Takata, MD, PhD, Tadashi Yoshino, MD, PhD, Naoki Ishizuka, PhD, Masahiko Oguchi, MD, PhD, Yukio Kobayashi, MD, PhD, Yasushi Isobe, MD, PhD, Kenichi Ishizawa, MD, Nobuko Kubota, MD, PhD, Kuniaki Itoh, MD, PhD, Noriko Usui, MD, PhD, Kana Miyazaki, MD, PhD, Izumi Wasada, RN, Shigeo Nakamura, MD, PhD, Yoshihiro Matsuno, MD, PhD, Kazuo Oshimi, MD, PhD, Tomohiro Kinoshita, MD, PhD, Kunihiro Tsukasaki, MD, PhD, Kensei Tobinai, MD, PhD

Blood (2013) 122 (21): 4280.

https://doi.org/10.1182/blood.V122.21.4280.4280

Published: 2013

Journal Articles

The MDM2 Antagonist Nutlin-3 Is Effective to Aggressive NK-Cell Neoplasms with Wild Type p53 in Hypoxia

Yoko Tabe, MD, PhD, Yasushi Isobe, MD, PhD, Koichi Sugimoto, MD, PhD, Linhua Jin, PhD, Kazuo Oshimi, MD, Takashi Miida, MD, PhD

Blood (2011) 118 (21): 4999.

https://doi.org/10.1182/blood.V118.21.4999.4999

Published: 2011

Journal Articles

Pretreatment EBV-DNA Copy Number Is Predictive for Response to SMILE Chemotherapy for Newly-Diagnosed Stage IV, Relapsed or Refractory Extranodal NK/T-Cell Lymphoma, Nasal Type: Results of NKTSG Phase II Study

Ritsuro Suzuki, MD, PhD, Hiroshi Kimura, MD, Yok-Lam Kwong, Yoshinobu Maeda, Chizuko Hashimoto, MD, Won Seog Kim, Cheolwon Suh, MD, Koji Izutsu, MD, PhD, Fumihiro Ishida, MD, Yoshinori Ito, Motoko Yamaguchi, MD, PhD, Junji Suzumiya, MD, Rie Hyo, Shigeo Nakamura, MD, Kazuo Oshimi, MD

Blood (2010) 116 (21): 2873.

https://doi.org/10.1182/blood.V116.21.2873.2873

Published: 2010

Journal Articles

Aggressive NK Cell Leukemia (ANKL): Experience with 34 Patients and Therapeutic Potentials of L-Asparaginase and Allogeneic Hematopoietic Cell Transplantation - A Japan-Korea Multicenter Study for ANKL (ANKL07) -

Fumihiro Ishida, MD, Won Seog Kim, MD, Young Hyeh Ko, MD, Junji Suzumiya, MD, Yasushi Isobe, MD, Kazuo Oshimi, MD, Shigeo Nakamura, MD, Ritsuro Suzuki, MD, PhD

Blood (2010) 116 (21): 3091.

https://doi.org/10.1182/blood.V116.21.3091.3091

Published: 2010

Journal Articles

Seven-Year Follow-up of Patients Receiving Imatinib for the Treatment of Chronic Myelogenous Leukemia by the TARGET System

Tetsuzo Tauchi, M.D., Masahiro Kizaki, M.D., Shinichiro Okamoto, M.D., Hideo Tanaka, M.D., Mitsune Tanimoto, M.D., Koiti Inokuchi, M.D., Tohru Murayama, M.D., Yoshio Saburi, M.D., Masayuki Hino, M.D., Mitsuru Tsudo, M.D., Taizo Shimomura, M.D., Yasushi Isobe, M.D., Kazuo Oshimi, MD, Kazuo Dan, M.D., Kazuma Ohyashiki, M.D., Yasuo Ikeda, M.D.

Blood (2010) 116 (21): 2287.

https://doi.org/10.1182/blood.V116.21.2287.2287

Published: 2010

Journal Articles

Prospective Measurement of EBV-DNA in Plasma and Peripheral Blood Mononuclear Cells of Extranodal NK/T-Cell Lymphoma, Nasal Type.

Ritsuro Suzuki, MD, PhD, Motoko Yamaguchi, MD, PhD, Koji Izutsu, MD, Go Yamamoto, Kenzo Takada, Yasuaki Harabuchi, Yasushi Isobe, Hiroshi Gomyo, Tadashi Koike, Masataka Okamoto, Junji Suzumiya, MD, Shigeo Nakamura, MD, Keisei Kawa, Kazuo Oshimi, MD

Blood (2009) 114 (22): 135.

https://doi.org/10.1182/blood.V114.22.135.135

Published: 2009

NARROW

STAT3 Mutations and Anemia with Pure Red Cell Aplasia Are the Distinctive Features of T Cell Receptor Gamma Delta Type Large Granular Lymphocyte Leukemia

Prognostic Value Of LMP1, CLA, NK-Cell Origin, and Pretreatment Bone Marrow EBER-ISH In Localized NK/T-Cell Lymphoma Prospectively Treated With Concurrent Chemoradiotherapy: An Ancillary Study Of Japan Clinical Oncology Group (JCOG) 0211

The MDM2 Antagonist Nutlin-3 Is Effective to Aggressive NK-Cell Neoplasms with Wild Type p53 in Hypoxia

Pretreatment EBV-DNA Copy Number Is Predictive for Response to SMILE Chemotherapy for Newly-Diagnosed Stage IV, Relapsed or Refractory Extranodal NK/T-Cell Lymphoma, Nasal Type: Results of NKTSG Phase II Study

Aggressive NK Cell Leukemia (ANKL): Experience with 34 Patients and Therapeutic Potentials of L-Asparaginase and Allogeneic Hematopoietic Cell Transplantation - A Japan-Korea Multicenter Study for ANKL (ANKL07) -

Seven-Year Follow-up of Patients Receiving Imatinib for the Treatment of Chronic Myelogenous Leukemia by the TARGET System

Prospective Measurement of EBV-DNA in Plasma and Peripheral Blood Mononuclear Cells of Extranodal NK/T-Cell Lymphoma, Nasal Type.

Email alerts

ASH Publications

American Society of Hematology

STAT3 Mutations and Anemia with Pure Red Cell Aplasia Are the Distinctive Features of T Cell Receptor Gamma Delta Type Large Granular Lymphocyte Leukemia

Prognostic Value Of LMP1, CLA, NK-Cell Origin, and Pretreatment Bone Marrow EBER-ISH In Localized NK/T-Cell Lymphoma Prospectively Treated With Concurrent Chemoradiotherapy: An Ancillary Study Of Japan Clinical Oncology Group (JCOG) 0211

The MDM2 Antagonist Nutlin-3 Is Effective to Aggressive NK-Cell Neoplasms with Wild Type p53 in Hypoxia

Pretreatment EBV-DNA Copy Number Is Predictive for Response to SMILE Chemotherapy for Newly-Diagnosed Stage IV, Relapsed or Refractory Extranodal NK/T-Cell Lymphoma, Nasal Type: Results of NKTSG Phase II Study

Aggressive NK Cell Leukemia (ANKL): Experience with 34 Patients and Therapeutic Potentials of L-Asparaginase and Allogeneic Hematopoietic Cell Transplantation - A Japan-Korea Multicenter Study for ANKL (ANKL07) -

Seven-Year Follow-up of Patients Receiving Imatinib for the Treatment of Chronic Myelogenous Leukemia by the TARGET System

Prospective Measurement of EBV-DNA in Plasma and Peripheral Blood Mononuclear Cells of Extranodal NK/T-Cell Lymphoma, Nasal Type.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only